Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • Protagonist Therapeutics News

    24,65 $ -4,01% -1,03 $
    In : 22,978 € | 20:34:08 Uhr Nasdaq aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A2AP32
    ISIN: US74366E1029
    US-Symbol: PTGX
    Typ: Aktie

    Protagonist Therapeutics News

    12.05.23 - PR Newswire
    Protagonist Reports Positive Results from Phase 1 and Pre-clinical Studies of Oral Interleukin-23 Receptor Antagonist JNJ-2113
    Protagonist Reports Positive Results from Phase 1 and Pre-​clinical Studies of Oral Interleukin-23 Receptor Antagonist JNJ-2113 PR Newswire
    11.05.23 - PR Newswire
    Protagonist Therapeutics to Participate in the JMP Securities Life Sciences Conference
    Protagonist Therapeutics to Participate in the JMP Securities Life Sciences Conference PR Newswire
    11.05.23 - PR Newswire
    Protagonist Therapeutics Announces Presentations at the 2023 Annual Congress of the European Hematology Association
    Protagonist Therapeutics Announces Presentations at the 2023 Annual Congress of the European Hematology Association PR Newswire
    04.05.23 - PR Newswire
    Protagonist Reports First Quarter 2023 Financial Results and Provides Corporate Update
    Protagonist Reports First Quarter 2023 Financial Results and Provides Corporate Update PR Newswire
    07.03.23 - PR Newswire
    Protagonist Therapeutics Announces Positive Topline Results for Phase 2b FRONTIER 1 Clinical Trial of Oral IL-23 Receptor Antagonist JNJ-2113 (PN-235) in Psoriasis
    Protagonist Therapeutics Announces Positive Topline Results for Phase 2b FRONTIER 1 Clinical Trial of Oral IL-23 Receptor Antagonist JNJ-2113 (PN-235) in Psoriasis PR Newswire
    21.12.22 - PR Newswire
    Protagonist Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
    Protagonist Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference PR Newswire
    01.12.22 - PR Newswire
    Protagonist Therapeutics to Participate in the JMP Securities Hematology and Oncology Summit
    Protagonist Therapeutics to Participate in the JMP Securities Hematology and Oncology Summit PR Newswire
    16.11.22 - PR Newswire
    Protagonist Therapeutics Reports Granting of Inducement Award
    Protagonist Therapeutics Reports Granting of Inducement Award PR Newswire
    08.11.22 - PR Newswire
    Protagonist Reports Third Quarter 2022 Financial Results and Provides Corporate Update
    Protagonist Reports Third Quarter 2022 Financial Results and Provides Corporate Update PR Newswire
    03.11.22 - PR Newswire
    Protagonist Therapeutics Announces Poster Presentations at the American Society of Hematology 2022 Annual Meeting
    Protagonist Therapeutics Announces Poster Presentations at the American Society of Hematology 2022 Annual Meeting PR Newswire
    02.11.22 - PR Newswire
    Protagonist Announces Appointment of Arturo Molina, M.D., M.S., F.A.C.P. as Chief Medical Officer
    Protagonist Announces Appointment of Arturo Molina, M.D., M.S., F.A.C.P. as Chief Medical Officer PR Newswire
    03.10.22 - PR Newswire
    Thinking about buying stock in Protagonist Therapeutics, BP, Nio, Axsome Therapeutics, or Petroleo Brasileiro?
    Thinking about buying stock in Protagonist Therapeutics, BP, Nio, Axsome Therapeutics, or Petroleo Brasileiro? PR Newswire
    20.09.22 - PR Newswire
    Protagonist Therapeutics Reports Granting of Inducement Award
    Protagonist Therapeutics Reports Granting of Inducement Award PR Newswire
    04.08.22 - PR Newswire
    Protagonist Reports Second Quarter 2022 Financial Results and Provides Corporate Update
    Protagonist Reports Second Quarter 2022 Financial Results and Provides Corporate Update PR Newswire
    19.07.22 - PR Newswire
    Protagonist Therapeutics Reports Granting of Inducement Award
    Protagonist Therapeutics Reports Granting of Inducement Award PR Newswire
    01.06.22 - PR Newswire
    Protagonist Therapeutics to Participate at the Jefferies Healthcare Conference
    Protagonist Therapeutics to Participate at the Jefferies Healthcare Conference PR Newswire
    26.05.22 - PR Newswire
    Protagonist Therapeutics to Present Updated Phase 2 Rusfertide Clinical Results in Polycythemia Vera (PV) at ASCO 2022
    Protagonist Therapeutics to Present Updated Phase 2 Rusfertide Clinical Results in Polycythemia Vera (PV) at ASCO 2022 PR Newswire
    11.05.22 - PR Newswire
    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Protagonist Therapeutics, Inc. - PTGX
    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Protagonist Therapeutics, Inc. - PTGX PR Newswire
    04.05.22 - PR Newswire
    Protagonist Reports First Quarter 2022 Financial Results and Provides Corporate Update
    Protagonist Reports First Quarter 2022 Financial Results and Provides Corporate Update PR Newswire
    25.04.22 - PR Newswire
    Protagonist Therapeutics Announces Topline Data from Phase 2 IDEAL Study of PN-943 in Ulcerative Colitis
    Protagonist Therapeutics Announces Topline Data from Phase 2 IDEAL Study of PN-943 in Ulcerative Colitis PR Newswire

    Newssuche

    Videos

    09:30 Uhr +26,02%
    Technical Trading: S&P 500 Short Chance
    S&P 500 Short Typ: Turbo Open End WKN: NG8FUZ Hebel: 31 Laufzeit: OpenEnd Einstieg: Market ... Mehr »